Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27488748 | 0.98 | EPHX2 (0.49) | EPHX2TSHRLMNAKMT2ACA12 | |
| SCHEMBL27489071 | 0.95 | TSHR (0.47) | EPHX2TSHRLMNAKMT2AALDH1A1 | |
| SCHEMBL27505820 | 0.91 | TSHR (0.50) | EPHX2TSHRLMNAKMT2AALDH1A1 | |
| SCHEMBL28241871 | 0.90 | EPHX2 (0.49) | EPHX2TSHRKMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL28241080 | 0.88 | EPHX2 (0.47) | EPHX2TSHRKMT2ACA12CA1 | |
| SCHEMBL2180615 | 0.81 | ALDH1A1 (0.46) | EPHX2TSHRLMNACA12CA1 | |
| SCHEMBL4362453 | 0.79 | ALDH1A1 (0.43) | EPHX2LMNAALDH1A1EPHX1 | |
| SCHEMBL17865084 | 0.79 | EPHX2 (0.46) | EPHX2KMT2ACA12CA1CA2 | |
| SCHEMBL27505427 | 0.78 | EPHX2 (0.46) | EPHX2TSHRLMNAKMT2ANAAA | |
| SCHEMBL8745876 | 0.76 | EPHX2 (0.49) | EPHX2TSHRLMNAKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | claimed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-1310872-C | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1878546-A | Combination comprising an alpha-2 delta ligand and an SSRI and/or SNRI for the treatment of depression and anxiety | WARNER LAMBERT CO (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1726015-A | Alpha 2 delta ligands for different pharmaceutical uses | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1660779-A | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1625393-A | Alpha 2 delta ligands to treat tinnitus | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1196671-C | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-04-13 | — | — | CN | disclosed |